Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Diabetes

Free Subscription Articles published in J Clin Invest Retrieve available abstracts of 58 articles: HTML format

Single Articles

March 2026
1. GUO C, Sodhi A
   Molecular stress and neurovascular injury in the diabetic retina.
   J Clin Invest. 2026;136:e200945.
   PubMed     Abstract available
   
   
   February 2026
2. FILIP P, Canna A, Grohn H, Moheet AA, et al
   Disrupted Neurovascular-Endocrine Coupling in Type 1 Diabetes with impaired awareness of hypoglycaemia.
   J Clin Invest. 2026 Feb 19:e199725. doi: 10.1172/JCI199725.
   PubMed     Abstract available
   
   
   
3. HEROLD KC, Perdigoto AL
   Predicting checkpoint inhibitor-associated autoimmune diabetes: prospects and limitations.
   J Clin Invest. 2026;136:e202477.
   PubMed     Abstract available
   
   
   
4. KAHLES F, Birkenfeld AL, Marx N
   GLP-1 and the cardiovascular system.
   J Clin Invest. 2026;136:e194748.
   PubMed     Abstract available
   
   
   
5. JALLEH RJ, Talley NJ, Horowitz M, Nauck MA, et al
   The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications.
   J Clin Invest. 2026;136:e194740.
   PubMed     Abstract available
   
   
   
6. AHMED A, Yadav P, Jensen M, Geasland K, et al
   Mitochondrial oxidants promote platelet activation and thrombotic susceptibility in prediabetes.
   J Clin Invest. 2025;136:e195662.
   PubMed     Abstract available
   
   
   
7. NAIK AS, Alakwaa FM, Nair V, McCown PJ, et al
   Metabolic surgery mitigates early kidney injury in obese youth with diabetes by suppressing mTORC1/JAK-STAT signaling.
   J Clin Invest. 2026 Feb 3:e198545. doi: 10.1172/JCI198545.
   PubMed     Abstract available
   
   
   January 2026
8. AUSTIN G, Tomas A
   Signaling architecture of the glucagon-like peptide-1 receptor.
   J Clin Invest. 2026;136:e194752.
   PubMed     Abstract available
   
   
   
9. CARDOSO P, Dennis JM, Pearson ER
   GLP-1RA precision medicine in people with type 2 diabetes: current insights and future prospects.
   J Clin Invest. 2026;136:e194742.
   PubMed     Abstract available
   
   
   
10. PERSAUD SP, DiPersio JF
    Preventing graft re-JAK-tion: safer transplant conditioning enables murine islet allograft tolerance and diabetes reversal.
    J Clin Invest. 2026;136:e201105.
    PubMed     Abstract available
    
    
    
11. REISER J, Hayek SS, Sever S
    The role of suPAR and related proteins in kidney, heart diseases, and diabetes.
    J Clin Invest. 2026;136:e197141.
    PubMed     Abstract available
    
    
    
12. GILANI A, Stein BD, Hoffmann A, Pereira de Lima R, et al
    Secretory kinase FAM20C triggers adipocyte dysfunction, inciting insulin resistance and inflammation in obesity.
    J Clin Invest. 2025;136:e191075.
    PubMed     Abstract available
    
    
    December 2025
13. CHEN HC, Bang MF, Wang HH, Shpargel KB, et al
    UTX coordinates TCF1 and STAT3 to control progenitor CD8+ T cell fate in autoimmune diabetes.
    J Clin Invest. 2025 Dec 16:e196325. doi: 10.1172/JCI196325.
    PubMed     Abstract available
    
    
    
14. HUANG X, Liu M, Gonzalez MV, Debnath R, et al
    Diabetes exacerbates destructive inflammation by activating theCD137L-CD137 axis in dendritic and gammadelta T-cells.
    J Clin Invest. 2025 Dec 11:e193289. doi: 10.1172/JCI193289.
    PubMed     Abstract available
    
    
    
15. BLACK PN, DiRusso CC
    FATP2 at the crossroads of fatty acid transport, lipotoxicity, and complex disease.
    J Clin Invest. 2025;135:e199873.
    PubMed     Abstract available
    
    
    
16. EIZIRIK DL, Zimath PL
    Diabetes research enters the biobank era: searching for the truth in a deep well.
    J Clin Invest. 2025;135:e199728.
    PubMed     Abstract available
    
    
    
17. KHAN S, Gaivin RJ, Liu Z, Li V, et al
    Fatty acid transport protein 2 inhibition enhances glucose tolerance through alpha cell-mediated GLP-1 secretion.
    J Clin Invest. 2025;135:e192011.
    PubMed     Abstract available
    
    
    November 2025
18. WU L, Wentworth JM, Liddle C, Fewings N, et al
    Pancreatic volume and immune biomarkers predict checkpoint inhibitor-associated autoimmune diabetes in humans.
    J Clin Invest. 2025 Nov 20:e192938. doi: 10.1172/JCI192938.
    PubMed     Abstract available
    
    
    
19. BHAGCHANDANI P, Ramos SA, Rodriguez B, Gu X, et al
    Curing autoimmune diabetes in mice with islet and hematopoietic cell transplantation after CD117 antibody-based conditioning.
    J Clin Invest. 2025 Nov 18:e190034. doi: 10.1172/JCI190034.
    PubMed     Abstract available
    
    
    
20. VALENCIA-RINCON E, Rai R, Chandra V, Wellberg EA, et al
    GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research.
    J Clin Invest. 2025;135:e194743.
    PubMed     Abstract available
    
    
    
21. COOPER ME, van Raalte DH
    GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity.
    J Clin Invest. 2025;135:e194749.
    PubMed     Abstract available
    
    
    
22. WONG CK, Drucker DJ
    Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits.
    J Clin Invest. 2025;135:e194751.
    PubMed     Abstract available
    
    
    
23. TAMBRALLI A, Knight JS
    Neutrophils take center stage in VEXAS syndrome pathogenesis.
    J Clin Invest. 2025;135:e199299.
    PubMed     Abstract available
    
    
    October 2025
24. KATZ LS, Scott DK, Stewart AF
    SIRT2 puts the brakes on human beta cell proliferation: therapeutic opportunities and next challenges.
    J Clin Invest. 2025;135:e197142.
    PubMed     Abstract available
    
    
    September 2025
25. SASSI G, Lemaitre P, Fernandez Calvo L, Lodi F, et al
    Neutrophil-enriched gene signature correlates with teplizumab therapy resistance in different stages of type 1 diabetes.
    J Clin Invest. 2025 Sep 30:e176403. doi: 10.1172/JCI176403.
    PubMed     Abstract available
    
    
    
26. DOS SANTOS T, Dai XQ, Jones RC, Spigelman AF, et al
    Altered immune and metabolic molecular pathways drive islet cell dysfunction in human type 1 diabetes.
    J Clin Invest. 2025 Sep 30:e195267. doi: 10.1172/JCI195267.
    PubMed     Abstract available
    
    
    
27. VIRGILIO E, Tielens S, Bonfield G, Nian FS, et al
    Recessive TMEM167A variants cause neonatal diabetes, microcephaly and epilepsy syndrome.
    J Clin Invest. 2025 Sep 9:e195756. doi: 10.1172/JCI195756.
    PubMed     Abstract available
    
    
    
28. MEAKIN PJ, Coull BM, Tuharska Z, McCaffery C, et al
    Expression of Concern for Elevated circulating amyloid concentrations in obesity and diabetes promote vascular dysfunction.
    J Clin Invest. 2025;135:e199125.
    PubMed    
    
    
    August 2025
29. TAVARES-FERREIRA D, Shen BQ, Mwirigi JM, Shiers S, et al
    Cell and molecular profiles in peripheral nerves shift toward inflammatory phenotypes in diabetic peripheral neuropathy.
    J Clin Invest. 2025 Aug 19:e184075. doi: 10.1172/JCI184075.
    PubMed     Abstract available
    
    
    
30. KONG YX, Rehan R, Moreno CL, Madsen S, et al
    SEC61B regulates calcium flux and platelet hyperreactivity in diabetes.
    J Clin Invest. 2025;135:e184597.
    PubMed     Abstract available
    
    
    
31. MIRZADEH Z, Morton GJ, Hirsch IB, Schwartz MW, et al
    An unexpected role for the brain in the pathogenesis of diabetic ketoacidosis.
    J Clin Invest. 2025;135:e196357.
    PubMed    
    
    
    
32. CHOE J, Belmonte P, Crotts S, Nguyen T, et al
    ST8Sia6 overexpression protects pancreatic beta cells from spontaneous autoimmune diabetes in nonobese diabetic mice.
    J Clin Invest. 2025;135:e181207.
    PubMed     Abstract available
    
    
    July 2025
33. SINGH AK, Bernabucci M, Dvorak NM, Haghighijoo Z, et al
    Sensory neuron-expressed FGF13 controls nociceptive signaling in diabetic neuropathy models.
    J Clin Invest. 2025;135:e183749.
    PubMed     Abstract available
    
    
    
34. LI X, Hu J, Huang Y, Zhang H, et al
    Trapalpha deficiency impairs the early events of insulin biosynthesis and glucose homeostasis.
    J Clin Invest. 2025;135:e179845.
    PubMed     Abstract available
    
    
    
35. NEWSOME PN, Loomba R
    Therapeutic horizons in metabolic dysfunction-associated steatohepatitis.
    J Clin Invest. 2025;135:e186425.
    PubMed     Abstract available
    
    
    June 2025
36. TOMLINSON JW
    Should GLP-1 receptor agonist therapy be used to treat obesity in Bardet-Biedl syndrome?
    J Clin Invest. 2025;135:e191822.
    PubMed     Abstract available
    
    
    May 2025
37. COSTANTINO S, Mohammed SA, Paneni F
    Endothelial dysfunction in patients with type 2 diabetes: the truth is in the blood.
    J Clin Invest. 2025;135:e193128.
    PubMed     Abstract available
    
    
    
38. SARKAR M, Kushner T
    Metabolic dysfunction-associated steatotic liver disease and pregnancy.
    J Clin Invest. 2025;135:e186426.
    PubMed     Abstract available
    
    
    
39. GOU Y, Glat M, Damian V, Bryan CL, et al
    AgRP neuron hyperactivity drives hyperglycemia in a mouse model of type 2 diabetes.
    J Clin Invest. 2025;135:e189842.
    PubMed     Abstract available
    
    
    
40. PETRIE GN, Mayo LM
    GLP-1 receptor agonists for the treatment of alcohol use disorder.
    J Clin Invest. 2025;135:e192414.
    PubMed     Abstract available
    
    
    April 2025
41. GATTU AK, Tanzer M, Yaron-Barir TM, Johnson JL, et al
    Cell-intrinsic insulin signaling defects in human iPS cell-derived hepatocytes in type 2 diabetes.
    J Clin Invest. 2025;135:e183513.
    PubMed     Abstract available
    
    
    March 2025
42. COLLADO A, Humoud R, Kontidou E, Eldh M, et al
    Erythrocyte-derived extracellular vesicles induce endothelial dysfunction through arginase-1 and oxidative stress in type 2 diabetes.
    J Clin Invest. 2025 Mar 20:e180900. doi: 10.1172/JCI180900.
    PubMed     Abstract available
    
    
    December 2024
43. CATTIN-ROY AN, Laffey KG, Le LB, Schrum AG, et al
    Reduced thymic IL-4 impairs negative T cell selection in nonobese diabetic mice.
    J Clin Invest. 2024;134:e163417.
    PubMed     Abstract available
    
    
    October 2024
44. CHOI YJ, Richard G, Zhang G, Hodgin JB, et al
    Attenuated kidney oxidative metabolism in young adults with type 1 diabetes.
    J Clin Invest. 2024 Oct 22:e183984. doi: 10.1172/JCI183984.
    PubMed     Abstract available
    
    
    
45. OTENG AB, Liu L, Cui Y, Gavrilova O, et al
    Activation of Gs signaling in mouse enteroendocrine K-cells greatly improves obesity- and diabetes-related metabolic deficits.
    J Clin Invest. 2024 Oct 22:e182325. doi: 10.1172/JCI182325.
    PubMed     Abstract available
    
    
    September 2024
46. DOLTON G, Bulek A, Wall A, Thomas H, et al
    HLA A*24:02-restricted T cell receptors cross-recognize bacterial and preproinsulin peptides in type 1 diabetes.
    J Clin Invest. 2024;134:e164535.
    PubMed     Abstract available
    
    
    
47. CAPERA J, Dustin ML
    Microbial mimics supersize the pathogenic self-response.
    J Clin Invest. 2024;134:e184046.
    PubMed     Abstract available
    
    
    August 2024
48. STERLING JK, Rajesh A, Droho S, Gong J, et al
    Retinal perivascular macrophages regulate immune cell infiltration during neuroinflammation in mouse models of ocular disease.
    J Clin Invest. 2024;134:e180904.
    PubMed     Abstract available
    
    
    
49. DING J, Nguyen AT, Lohman K, Hensley MT, et al
    LXR signaling pathways link cholesterol metabolism with risk for prediabetes and diabetes.
    J Clin Invest. 2024;134:e185290.
    PubMed    
    
    
    
50. LLEDO-DELGADO A, Preston-Hurlburt P, Currie S, Clark P, et al
    Teplizumab induces persistent changes in the antigen-speci fi c repertoire in individuals at-risk for type 1 diabetes.
    J Clin Invest. 2024 Aug 13:e177492. doi: 10.1172/JCI177492.
    PubMed     Abstract available
    
    
    July 2024
51. SCHRADER LA, Ronnekleiv-Kelly SM, Hogenesch JB, Bradfield CA, et al
    Circadian disruption, clock genes, and metabolic health.
    J Clin Invest. 2024;134:e170998.
    PubMed     Abstract available
    
    
    June 2024
52. MURALIDHARAN C, Huang F, Enriquez JR, Wang JE, et al
    Inhibition of the eukaryotic initiation factor-2-alpha kinase PERK decreases risk of autoimmune diabetes in mice.
    J Clin Invest. 2024 Jun 18:e176136. doi: 10.1172/JCI176136.
    PubMed     Abstract available
    
    
    
53. HAEMMERLE MW, Scota AV, Khosravifar M, Varney MJ, et al
    RNA-binding protein PCBP2 regulates pancreatic beta cell function and adaptation to glucose.
    J Clin Invest. 2024;134:e172436.
    PubMed     Abstract available
    
    
    May 2024
54. DING J, Nguyen AT, Lohman K, Hensley MT, et al
    LXR signaling pathways link cholesterol metabolism with risk for prediabetes and diabetes.
    J Clin Invest. 2024;134:e173278.
    PubMed     Abstract available
    
    
    
55. SABADELL-BASALLOTE J, Astiarraga B, Castano C, Ejarque M, et al
    SUCNR1 regulates insulin secretion and glucose elevates the succinate response in people with prediabetes.
    J Clin Invest. 2024;134:e173214.
    PubMed     Abstract available
    
    
    April 2024
56. YANG J, Zhuang H, Li J, Nunez-Nescolarde AB, et al
    The secreted micropeptide C4orf48 enhances renal fibrosis via an RNA-binding mechanism.
    J Clin Invest. 2024;134:e178392.
    PubMed     Abstract available
    
    
    March 2024
57. DI GIUSEPPE G, Soldovieri L, Ciccarelli G, Ferraro PM, et al
    Reduced incretin effect precedes diabetes development following duodenopancreatectomy in subjects without diabetes.
    J Clin Invest. 2024 Mar 12:e175133. doi: 10.1172/JCI175133.
    PubMed    
    
    
    
58. DEFRONZO RA
    SGLT2 inhibitors: cardiorenal metabolic drugs for the ages.
    J Clin Invest. 2024;134:e177625.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum